Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 16

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
 an aggregate of 75,335 shares of common stock and warrants to purchase 75,335 shares of common stock (the “January 2025 Warrants”).
    The shares and January 2025 Warrants were sold on a combined basis for consideration of $29.82 for one share and one January 2025
    Warrant. The January 2025 Warrants are immediately exercisable at an exercise price of $26.32 per share and expire five years from
    the date of issuance. The total net proceeds were approximately $2.0 million, after deducting placement agent and other offering
    expenses in the amount of approximately $0.25 million. In February 2025, the Company filed a registration statement to register the
    resale by the investors of the shares of common stock and shares of common stock issuable upon exercise of the January 2025 Warrants.
    The registration statement was declared effective on February 11, 2025. In addition, in connection with the January 2025 Offering,
    the Company issued to the placement agent and its designees warrants to purchase an aggregate of 5,268 shares of common stock at
    an exercise price of $32.90. The placement agent warrants are exercisable six months from the date of issuance and expire on the
    fifth anniversary of the issue date. The fair value of a warrant to purchase one share of common stock that was issued to the placement
    agent was $20.72.

    c.
    On
    February 12, 2025, the Company entered into the SEPA with Yorkville, which provides that, upon the terms and
    subject to the restrictions and satisfaction of the conditions in the SEPA, Yorkville is committed to purchase up to an aggregate of
    $20.0 million
    of the Company’s shares of common stock over a 36-month period. At the Company’s option, the shares of common stock
    would be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily VWAPs during a three
    consecutive trading day period commencing on the date that the Company, subject to certain limitations, delivers a notice to
    Yorkville that the Company is committing Yorkville to purchase such shares of common stock. The Company may also specify a certain
    minimum acceptable price per share in each advance. The Company will control the timing and amount of sales of the Company’s